SCA Pharmaceuticals Recalls Products Due to Potential Contamination

Article

The company is recalling several injectable products because of possible microbial contamination.

On Oct. 20, 2017, SCA Pharmaceuticals LLC announced it was voluntarily recalling several lots of injectable products to the hospital level because of a potential for microbial contamination.  The recalled products were distributed nationwide to hospitals.

The recalled products include Succinylcholine Chloride 20 mg/mL 10 mL syringe, Fentanyl 2 mcg/mL + Bupivacaine 0.125% in 250 mL 0.9% Sodium Chloride, Oxytocin 30 units added to 500 mL Lactated Ringers, and Calcium Gluconate 2 g added to 50 mL 0.9% Sodium Chloride. A complete list of recalled products can be found on FDA’s website.

While the company has not received any reports of adverse events as of the date of the recall, it cautions that using products that are intended to be sterile but may be contaminated may result in serious or even life-threatening infections. The company stated in a press release that patients should contact their healthcare provider if they experience any problems associated with the recalled products. Adverse events may be reported to FDA via their website

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes